10-Q: Travere Therapeutics Reports Strong Q3 Revenue Growth

Travere Therapeutics, Inc. announced significant revenue growth in the third quarter of 2025, driven by strong FILSPARI sales and milestone payments, while narrowing its net loss for the nine-month period.

Summary

• Net product sales for the three months ended September 30, 2025, increased by $52.149 million to $113.150 million, compared to $61.001 million for the same period in 2024.
• Net product sales for the nine months ended September 30, 2025, increased by $130.691 million to $283.852 million, compared to $153.161 million for the same period in 2024.
• FILSPARI sales were $90.900 million in Q3 2025, up from $35.619 million in Q3 2024, and $218.668 million for the nine months 2025, up from $82.578 million in the prior year period.
• License and collaboration revenue surged to $51.709 million in Q3 2025 from $1.897 million in Q3 2024, and to $77.187 million for the nine months 2025 from $5.227 million in the prior year period.
• Total revenue for Q3 2025 reached $164.859 million, a significant increase from $62.898 million in Q3 2024.
• The company reported a net income of $25.706 million in Q3 2025, a substantial improvement from a net loss of $54.811 million in Q3 2024.
• Net loss for the nine months ended September 30, 2025, narrowed to $28.275 million, compared to a net loss of $261.281 million for the same period in 2024.
• Basic earnings per share for Q3 2025 was $0.29, compared to a loss of $0.70 in Q3 2024.
• Cash and cash equivalents increased to $110.930 million as of September 30, 2025, from $58.535 million at December 31, 2024.
• The FDA accepted the supplemental New Drug Application (sNDA) for FILSPARI for the treatment of Focal Segmental Glomerulosclerosis (FSGS) and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 13, 2026, with no advisory committee meeting needed.
• Enrollment in the Phase 3 HARMONY Study for pegtibatinase was voluntarily paused in September 2024 due to manufacturing scale-up issues, with a goal to restart enrollment in 2026.
• Renalys Pharma, Inc., the company's partner for sparsentan in Japan and other Asian countries, completed data collection for the primary endpoint in its Phase 3 IgAN clinical trial and reached an agreement with the PMDA for two new Phase 3 trials in FSGS and Alport syndrome.
• Renalys Pharma, Inc. announced a definitive stock purchase agreement with Chugai Pharmaceutical Co., Ltd., under which Chugai will acquire full ownership of Renalys, impacting Travere's future payments from the collaboration.

Sentiment

Score: 7

Explanation: The company demonstrated robust revenue growth and a substantial improvement in profitability, driven by strong performance of FILSPARI and key milestone achievements. Positive regulatory developments for FILSPARI in FSGS also contribute to a favorable outlook. However, the delay in the pegtibatinase program and ongoing generic competition for Thiola present notable challenges.

Positives

• Total revenue for the three months ended September 30, 2025, increased by $101.961 million to $164.859 million, compared to $62.898 million for the same period in 2024.
• Total revenue for the nine months ended September 30, 2025, increased by $202.651 million to $361.039 million, compared to $158.388 million for the same period in 2024.
• FILSPARI net product sales grew significantly to $90.900 million in Q3 2025 from $35.619 million in Q3 2024, and to $218.668 million for the nine months 2025 from $82.578 million in the prior year period.
• Achieved a net income of $25.706 million in Q3 2025, a substantial improvement from a net loss of $54.811 million in Q3 2024.
• Reduced net loss for the nine months ended September 30, 2025, to $28.275 million from $261.281 million in the prior year period.
• Received a $17.5 million regulatory milestone payment in May 2025 for FILSPARI's standard marketing authorization in Europe.
• Recognized a $40.0 million market access milestone in September 2025, with payment received in Q4 2025, under the CSL Vifor License Agreement.
• The FDA approved updated REMS labeling for FILSPARI in August 2025, reducing liver monitoring frequency to every three months and removing the embryo-fetal toxicity monitoring requirement.
• The FDA accepted the sNDA for FILSPARI in FSGS and assigned a PDUFA target action date of January 13, 2026, and subsequently informed the company that an advisory committee meeting is no longer needed, potentially streamlining the approval process.
• Renalys Pharma completed data collection for the primary endpoint in the Phase 3 clinical trial of sparsentan for IgAN in Japan and reached an agreement with the PMDA regarding development plans for two new Phase 3 clinical trials of sparsentan in FSGS and Alport syndrome in Japan.
• Cash and cash equivalents increased to $110.930 million as of September 30, 2025, from $58.535 million at December 31, 2024.
• Net working capital improved to $236.036 million as of September 30, 2025, from $215.951 million at December 31, 2024.

Negatives

• Tiopronin product sales decreased by $3.132 million to $22.250 million in Q3 2025 from $25.382 million in Q3 2024, and by $5.399 million to $65.184 million for the nine months 2025 from $70.583 million in the prior year period, primarily due to generic competition.
• Marketable debt securities decreased significantly to $143.600 million as of September 30, 2025, from $312.166 million at December 31, 2024, partly due to the repayment of the 2025 convertible senior notes.
• Voluntary pause of enrollment in the Phase 3 HARMONY Study for pegtibatinase due to manufacturing scale-up issues, delaying the program with a goal to restart enrollment in 2026.
• Interest income decreased for both the three and nine months ended September 30, 2025, due to a decrease in the overall balance of interest-bearing security investments held.
• Accumulated deficit increased to $(1,475.442) million as of September 30, 2025, from $(1,447.167) million at December 31, 2024.
• The Phase 3 DUPLEX Study of sparsentan in FSGS did not achieve its two-year primary endpoint (eGFR slope) with statistical significance over the active control irbesartan.

Risks

• Future prospects are highly dependent upon the ability to successfully develop and execute commercialization strategies for products, including FILSPARI, and to attain market acceptance among physicians, patients, and healthcare payers.
• International trade policies, including tariffs, sanctions, and trade barriers, may adversely affect business, financial condition, results of operations, and prospects.
• Clinical trials are expensive and time-consuming and may fail to demonstrate the safety and efficacy of product candidates.
• Success in nonclinical testing and early clinical trials does not ensure that later clinical trials will be successful.
• Communications and/or feedback from regulatory authorities related to current or planned future clinical trials do not guarantee any particular outcome from or timeline for regulatory review, and expedited regulatory review pathways may not actually lead to faster development or approval.
• To operate the business and increase adoption and sales of products, the company needs to continue to develop its commercial organization, including maintaining a highly experienced and skilled workforce with qualified sales representatives.
• Interim, topline, and preliminary data from clinical trials that are announced or published may change materially as more patient data become available and audit and verification procedures are complete.
• The company faces substantial generic and other competition, and operating results will suffer if it fails to compete effectively.
• Healthcare reform initiatives, unfavorable pricing regulations, and changes in reimbursement practices of third-party payers or patients' access to insurance coverage could affect the pricing of and demand for products.
• The company is dependent on third parties to manufacture and distribute its products.
• The market opportunities for products and product candidates may be smaller than believed.
• Product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval or commercialization.
• The company does not currently have patent protection for certain commercial products; if unable to obtain and maintain protection for intellectual property, their value will be adversely affected.
• The company expects to rely on orphan drug status to develop and commercialize certain products and product candidates, but orphan drug designations may not confer marketing exclusivity or other expected commercial benefits.
• If unable to obtain and maintain coverage and adequate reimbursement from governments or third-party payers for any products that may be developed, or if unable to obtain acceptable prices for those products, prospects for generating revenue and achieving profitability will suffer.
• The company will likely experience fluctuations in operating results and could incur substantial losses.
• Negative publicity regarding any products could impair the ability to market such product and may require spending time and money to address these issues.
• The company may need substantial funding and may be unable to raise capital when needed.
• The company may not receive some or all of the potential milestone and/or royalty payments from corporate and licensing transactions.
• The company may be unable to successfully integrate new products or businesses acquired.
• The company may become involved in litigation matters, which could result in substantial costs, divert management's attention, and otherwise have a material adverse effect on business, operating results, or financial condition.
• The company is subject to significant ongoing regulatory obligations and oversight, which may result in significant additional expense and may limit commercial success.
• Unstable market, economic, and geopolitical conditions may have serious adverse consequences on business, financial condition, and stock price.
• Indebtedness could adversely affect financial condition.
• The company may be unable to raise the funds necessary to repurchase the 2029 Notes for cash following a fundamental change, or to pay any cash amounts due upon conversion, and future indebtedness may limit the ability to repurchase the 2029 Notes or pay cash upon their conversion.
• A default under the 2029 Notes may have a material adverse effect on financial condition.
• Provisions of the 2029 Notes could discourage an acquisition of the company by a third party.
• Conversion of the Notes may dilute the ownership interest of existing stockholders, including holders who had previously converted their 2029 Notes.
• Business could be negatively impacted by environmental, social, and corporate governance (ESG) matters or reporting of such matters.
• The withdrawal of the United Kingdom from the European Union (Brexit) may adversely impact the ability to obtain regulatory approvals of product candidates in the United Kingdom, result in restrictions or imposition of taxes and duties for importing product candidates into the United Kingdom, and may require incurring additional expenses.
• Business disruptions could seriously harm future revenue and financial condition and increase costs and expenses.
• If material weaknesses in internal control over financial reporting are discovered or occur in the future, consolidated financial statements may contain material misstatements and the company could be required to restate financial results.
• Adverse developments affecting the financial services industry could adversely affect current and projected business operations and financial condition and results of operations.
• The company maintains cash at financial institutions, often in balances that exceed federally insured limits.
• Risks related to the use of artificial intelligence technologies could adversely affect business, financial condition, and/or operating results.
• Uncertainties in the interpretation and application of existing, new, and proposed tax laws and regulations could materially affect tax obligations and effective tax rate.
• The ability to use net operating loss carryforwards and certain other tax attributes to offset future taxable income and taxes may be subject to limitations.
• Changes in funding for the FDA, the SEC, and other government agencies or regulatory authorities could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner, or otherwise prevent those agencies from performing normal functions on which the operation of business may rely.

Future Outlook

The company expects operating results to vary significantly quarter-to-quarter and year-to-year due to investments in research and development, particularly clinical and nonclinical development activities. Certain expenses are anticipated to increase, including those for clinical trials, R&D, marketing, sales, distribution, quality systems, and operational/financial systems. Management believes that available cash and short-term investments, combined with anticipated cash from operations, will be sufficient to fund operations beyond the next 12 months. However, funding operations in subsequent years may require additional debt or equity financing or refinancing existing debt. The company may incur significant operating losses over the next several years, with profitability dependent on successful product development, regulatory approvals, market commercialization, and potential in-licensing. Additional FILSPARI milestones are anticipated with potential future payments. The goal is to restart enrollment in the Phase 3 HARMONY Study for pegtibatinase in 2026. Renalys expects results from the urine protein/creatinine ratio (UP/C) endpoint in the Japan IgAN study in the second half of 2025.

Management Comments

• Our approach centers on advancing our innovative pipeline with multiple late-stage clinical programs targeting rare diseases with significant unmet medical needs.
• Upon approval of any of our late-stage programs, we intend to leverage the skills of our talented commercial organization which has successfully identified, supported and treated patients prescribed our approved products for over ten years.
• We invest revenues from our commercial portfolio into our pipeline with the goal of delivering new treatments for diseases with limited or no approved therapies.
• We estimate more than 70,000 patients in the United States to be addressable under FILSPARI's full approval indication.
• While we intend to utilize our continued clinical trial experience with FILSPARI and post-marketing data gathering commitment to potentially support lifting of the liver monitoring REMS in the future following sufficient experience with FILSPARI and if supported by the data, there is no guarantee that such efforts will be successful.
• We are encouraged by the results [of DUPLEX Study in FSGS], including the pre-specified secondary endpoints on proteinuria and exploratory endpoints, including renal outcomes, which trended favorably for sparsentan.
• If approved, FILSPARI could become the first and only FDA-approved medicine indicated for FSGS.
• We have successfully manufactured the first commercial-scale batches and are engaging with regulators to restart enrollment in the Phase 3 HARMONY Study in 2026.
• We believe that our available cash and short-term investments as of the date of this filing, together with anticipated cash generated from operations, will be sufficient to fund our anticipated level of operations beyond the next 12 months from the date of this filing.

Industry Context

FILSPARI's position as the first non-immunosuppressive, oral, once-daily therapy directly targeting glomerular injury in IgAN highlights a significant advancement in rare kidney disease treatment, setting a new standard in a rapidly evolving competitive landscape, as evidenced by Novartis's recent accelerated approval of atrasentan. The high unmet need in FSGS, with no current FDA-approved pharmacologic treatments, positions FILSPARI for a potentially transformative market entry if approved. The collaborative PARASOL project's focus on proteinuria-based endpoints for FSGS reflects a broader industry trend towards refining clinical trial methodologies and regulatory acceptance for rare kidney diseases. The acquisition of Renalys by Chugai Pharmaceutical underscores the strategic importance of partnerships and consolidation in expanding market access for rare disease therapies, particularly in key Asian markets. Ongoing generic competition for older products like Thiola is a persistent challenge across the pharmaceutical industry, impacting revenue from mature portfolios. Furthermore, the company operates within a dynamic regulatory environment influenced by healthcare reform initiatives, drug pricing scrutiny, and emerging considerations around ESG matters and the use of AI/ML technologies, all of which are shaping the broader pharmaceutical industry.

Comparison to Industry Standards

• FILSPARI is the only oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney by blocking two critical pathways of IgAN disease progression (endothelin-1 and angiotensin II), differentiating it from other therapies.
• The PROTECT Study for FILSPARI in IgAN is noted as the largest head-to-head interventional study to date in IgAN, indicating a robust clinical development effort compared to industry norms.
• The Phase 3 DUPLEX Study and Phase 2 DUET Study for sparsentan in FSGS are described as two of the largest and most rigorous head-to-head interventional studies conducted to date in FSGS, positioning FILSPARI as a potential first-in-class FDA-approved medicine for this condition.
• Novartis's atrasentan received accelerated approval in April 2025 to reduce proteinuria in adults with primary IgAN, representing a direct competitor to FILSPARI in the IgAN market.
• The PARASOL project's findings, which support the importance of proteinuria in FSGS, align with FILSPARI's demonstrated efficacy in proteinuria reduction in the DUPLEX Study, suggesting the company's clinical data is consistent with evolving scientific consensus on endpoints in rare kidney diseases.
• The company's reliance on third-party manufacturers and distributors is a common industry practice, but also introduces supply chain and quality control risks that require diligent oversight.
• Orphan Drug Designations for sparsentan and pegtibatinase align with standard regulatory strategies for rare disease therapies, offering potential market exclusivity periods (e.g., seven years in the U.S. for IgAN).

Legal Proceedings

• From time to time in the normal course of business, the company is subject to various legal matters such as threatened or pending claims or litigation.
• The company does not believe it is a party to any claim or litigation in which the outcome would individually or in the aggregate be reasonably expected to have a material adverse effect on its results of operations or financial condition.
• In 2020, the company completed its response to a civil investigative demand from the FTC related to the marketing, sale, distribution, and pricing of its products, including Thiola; the investigation remains open, but the FTC has not indicated additional questions or initiated claims.
• The company filed an appeal with the Competent Administrative Court regarding a French rebate accrual of approximately $6.2 million for Kolbam, which was paid in November 2024.
• In November 2020, a third party filed an opposition to European Patent No. EP3222277 (the '277 EP Patent) related to sparsentan in the European Patent Office ('EPO'); the company is vigorously defending the patent.

Related Party Transactions

• The company has ongoing license and collaboration agreements with CSL Vifor, Renalys Pharma, Ligand Pharmaceuticals, and Mission Pharmacal, which involve milestone and royalty payments.
• As a minority shareholder in Renalys, Travere is entitled to receive a portion of the upfront payment at the closing of Chugai Pharmaceutical Co., Ltd.'s acquisition of Renalys, and will be eligible for future payments upon the achievement of specified regulatory milestones for sparsentan and royalties on net sales in Japan, South Korea, and Taiwan.

Stakeholder Impact

• Shareholders: Potential for increased value due to strong revenue growth, improved profitability, and positive regulatory progress for FILSPARI. Dilution risk from potential future equity offerings or conversion of convertible notes. Risk of stock price volatility.
• Patients: Continued access to FILSPARI for IgAN, potential new treatment for FSGS if approved, and ongoing development of pegtibatinase for HCU. Reduced liver monitoring frequency for FILSPARI is a positive for patients.
• Employees: Increased headcount in R&D, but also competition for talent. A restructuring plan in December 2023 primarily impacted non-field-based employees.
• CSL Vifor: Continued collaboration for FILSPARI commercialization in licensed territories, with milestone payments received.
• Renalys Pharma: Acquisition by Chugai Pharmaceutical will change the dynamics of the partnership, with Travere receiving upfront and future milestone/royalty payments.
• Ligand Pharmaceuticals: Entitled to escalating royalties (15-17%) on FILSPARI net sales and milestone payments.
• Mission Pharmacal: Entitled to a guaranteed minimum royalty or 20% of Thiola net sales.
• Creditors (2029 Notes holders): Repayment of 2025 Notes completed. 2029 Notes remain outstanding, with interest payments and potential conversion/repurchase rights.

Next Steps

• Continue to develop commercial organization and sales force for FILSPARI.
• Engage with regulators to restart enrollment in the Phase 3 HARMONY Study for pegtibatinase in 2026.
• Await PDUFA target action date of January 13, 2026, for FDA decision on FILSPARI sNDA for FSGS.
• Renalys to pursue regulatory approval for sparsentan in Japan based on UP/C endpoint results expected in the second half of 2025.
• Renalys to initiate two new Phase 3 clinical trials for sparsentan in FSGS and Alport syndrome in Japan.
• Travere to receive a portion of the upfront payment from Chugai's acquisition of Renalys and be eligible for future regulatory milestones and royalties.
• Monitor and manage potential impacts of international trade policies, healthcare reform, and AI/ML regulations.
• Continue to evaluate potential historical ownership changes and future ownership changes that could limit NOL carryforwards.
• Pursue appeal of French rebate accrual of $6.2 million.

Key Dates

Recommendation

The company demonstrated exceptional financial performance in Q3 2025, achieving net income and significantly narrowing its year-to-date net loss, driven by robust FILSPARI sales and substantial milestone payments. The FDA's acceptance of the sNDA for FILSPARI in FSGS with a PDUFA date and no advisory committee meeting reduces regulatory uncertainty and signals a clear path towards potential approval for a high-unmet-need indication. The acquisition of Renalys by Chugai Pharmaceutical also provides a clear monetization path for the Asian rights to sparsentan. While the delay in the pegtibatinase program and generic competition for Thiola are headwinds, the strong commercial execution of FILSPARI and the promising pipeline developments, particularly for FSGS, suggest significant upside potential. The company's improved liquidity position further supports its strategic objectives.

Keywords

Travere Therapeutics, TVTX, Biopharmaceutical, Rare Kidney Disease, Metabolic Disease, FILSPARI, sparsentan, IgAN, FSGS, Thiola, Tiopronin, Cystinuria, Pegtibatinase, Homocystinuria, HCU, CSL Vifor, Renalys Pharma, Chugai Pharmaceutical, FDA Approval, Marketing Authorization, Clinical Trials, Orphan Drug, Financial Results, Revenue Growth, Net Income, R&D, SEC Filing, 10-Q